报告时间：2025年10月11日（星期六）10:00-11:30

报告地点：学术会议中心一楼报告厅

报告人：杨义燕 院士

工作单位：新加坡生物工程技术研究所、新加坡国立大学医学院

举办单位：化学与化工学院，高值催化转化与反应工程安徽省重点实验室，安徽省柔性智能材料创制与应用工程研究中心

报告人简介：

新加坡生物工程技术研究所研究员、新加坡国立大学医学院研究教授。本科毕业于合肥工业大学，博士毕业于清华大学。2016年当选美国医学与生物工程院（American Institute for Medical and Biological Engineering，AIMBE）院士，2021年当选新加坡工程院（ Academy of Engineering Singapore, SAEng）院士。现担任Nanomedicine: Nanotechnology, Biology and Medicine副主编以及Advanced Healthcare Materials编委。研究方向为基于可降解大分子的抗菌和抗肿瘤药物/材料及其递送系统。在Nature系列（Nat. Mater., Nat. Nanotechnol., Nat. Chem., Nat. Biomedical Eng., Nat. Comms）等权威期刊发表论文300余篇，H指数99，多次入选全球高被引学者和全球顶尖前10万科学家，累计纵向和横向合作经费超过1亿元人民币。曾以第一完成人获得国家科委科技进步二等奖和国家教委科技进步一等奖；曾被评为新加坡“当代最有影响力的女性”（Great Women of Our Time）；多次入选全球1%高被引学者；主导研发的抗菌高分子材料入选《科学美国人》“改变世界的十大科技创意”（Top 10 World Changing Ideas），开发全球首款高分子抗菌喷雾Tirsafe®已在新加坡上市。

报告简介：

        The emergence of drug resistance in cancer and infectious diseases presents one of the most formidable challenges to modern medicine, undermining the efficacy of established therapies. In this talk, I will present our work on the design and engineering of innovative macromolecules to overcome resistance and enable next-generation targeted gene delivery. We developed antimicrobial polymers that eradicate bacterial and fungal pathogens with high potency, while uniquely preventing resistance even after repeated use. Remarkably, these polymers can also reverse antibiotic resistance phenotypes, thereby restoring the utility of conventional antibiotics. Extending this approach, we engineered anticancer polymers that eliminate tumor cells effectively without inducing resistance, offering a promising new class of therapeutic agents. More recently, we advanced the development of novel lipid nanoparticle (LNP) systems tailored for precise mRNA delivery. These LNPs achieve efficient and tissue-specific transfection while avoiding immunogenicity. They have demonstrated robust efficacy in delivering mRNA vaccines against viral infection and cancer, opening the door to safe, scalable, and durable gene therapies. Together, these innovations illustrate how macromolecular engineering can reimagine therapeutic paradigms, transforming our ability to combat resistance and harness the full potential of gene-based medicine.